[New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
In a 28-year-old patient with a large uterine leiomyoma, complete tumor regression was achieved by the LHRH agonist Zoladex (ICI 118.630) when administered three times. During the follow-up period of three months, new myoma growth did not occur. On the basis of this case study, it is necessary to discuss a new therapy concept for the differentiated treatment of uterine leiomyomata in young women with a desire for pregnancy.
Gesenhues
T
T
Zentrum für Frauenheilkunde und Geburtshilfe der Philipps-Universität Marburg.
Hackenberg
R
R
Diechert
U
U
Duda
V
V
Sturm
G
G
Schulz
K D
KD
D000328:Adult; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D007889:Leiomyoma / Q000175:diagnosis / Q000188:drug therapy*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D014463:Ultrasonography; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014599:Uterus / Q000473:pathology
D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin
Neue Möglichkeiten zur differenzierten Therapie von Leiomyomen des Uterus mit dem GnRH-Agonisten "Zoladex".